Clearmind Medicine Secures FDA IND Approval for Alcoholism Trial
Ticker: CMND · Form: 6-K · Filed: Jul 16, 2024 · CIK: 1892500
Sentiment: bullish
Topics: FDA approval, patent application, clinical trial, pharmaceuticals
TL;DR
FDA greenlights Clearmind's alcoholism trial, plus patent filing for weight-loss drug.
AI Summary
Clearmind Medicine Inc. announced on July 16, 2024, that it has submitted a US patent application for its treatment targeting metabolic syndrome and weight loss. Additionally, the company received Investigational New Drug (IND) approval from the FDA to commence a Phase I/IIa clinical trial for its innovative alcoholism treatment.
Why It Matters
FDA approval for a clinical trial is a significant step towards potentially bringing a new treatment for alcoholism to market, while the patent application signals innovation in metabolic syndrome and weight-loss therapies.
Risk Assessment
Risk Level: medium — The company is advancing clinical trials and patent applications, which carry inherent risks of failure and regulatory hurdles.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- FDA (company) — Regulatory body granting IND approval
- July 16, 2024 (date) — Date of press releases
FAQ
What is the specific indication for the US patent application submitted by Clearmind Medicine?
The US patent application is for treating metabolic syndrome and weight-loss.
What type of clinical trial has Clearmind Medicine received FDA IND approval for?
Clearmind Medicine has received FDA IND approval to start a Phase I/IIa clinical trial.
What is the innovative treatment that Clearmind Medicine is developing for?
The innovative treatment is for alcoholism.
What is the filing date of this 6-K report?
The filing date of this 6-K report is July 16, 2024.
What other regulatory filing does Clearmind Medicine indicate it files annually?
Clearmind Medicine indicates it files annual reports under cover of Form 20-F.
Filing Stats: 340 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-07-16 16:01:03
Filing Documents
- ea0209491-6k_clearmind.htm (6-K) — 11KB
- ea020949102ex99-1_clearmind.htm (EX-99.1) — 13KB
- ea020949102ex99-2_clearmind.htm (EX-99.2) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- ex99-2_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-061772.txt ( ) — 44KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: July 16, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 2